BPC-157

BPC-157 is a synthetic 15-amino-acid peptide ("pentadecapeptide") originally isolated from human gastric juice. The evidence below is almost entirely from animal studies — flagged per finding.

Tendon repair — animal studies: full recovery of tendon integrity after a transected Achilles tendon — improved load-to-failure, functional index scores, and collagen/fibroblast formation. Staresinic et al., J Orthop Res, 2003

Gastric ulcer protection — animal studies: reduced ulcer lesion size at 200-800 ng/kg, outperforming famotidine at the higher tested dose. Xue et al., World J Gastroenterol, 2004

Muscle healing — animal studies: consistently improved healing of fully transected quadriceps muscle across a 72-day period — functional, structural, and biomechanical measures all improved. Staresinic et al., J Orthop Res, 2006 Separately, reduced hematoma/edema and normalized muscle-injury blood markers in a muscle crush injury model. Novinscak et al., Surgery Today, 2008

Neurological — animal studies: reduced brain edema and improved early outcomes in a traumatic brain injury model. Tudor et al., Regul Pept, 2010 Faster axonal regeneration and improved nerve fiber density in a sciatic nerve injury model. Gjurasin et al., Regul Pept, 2010

Angiogenesis — animal studies: increased vessel density and accelerated blood-flow recovery in ischemic limbs via VEGFR2 pathway activation. Hsieh et al., J Mol Med, 2017

A 2019 review of the broader tendon/ligament/muscle literature concludes results are "consistently positive" across studies, while cautioning this is almost entirely rodent data with no confirmed human efficacy data. Gwyer, Wragg & Wilson, Cell Tissue Res, 2019

No human clinical dose exists for BPC-157 self-administration. What follows are the real reference points found in the literature — animal doses (context only) and human pilot-study doses (all supervised clinical settings, not self-administration).

Animal dosing (context, not a human protocol): Achilles tendon study used 10 μg/kg, 10 ng/kg, or 10 pg/kg intraperitoneal, once daily. Gastric ulcer study used 200-800 ng/kg intramuscular or intragastric.

Human pilot dosing (clinical settings): intra-articular knee injection in a 16-patient chart review; intravesical (bladder) injection, 10mg total, in a 12-patient interstitial cystitis pilot; intravenous infusion up to 20mg in a 2-person safety pilot.

Community-use discussion commonly references a subcutaneous protocol in the 200-500mcg/day range with a multi-week on/off cycling pattern. This figure does not trace back to a clinical trial in anything reviewed here — treat it as reported community practice, not a validated dose.

A 5mg vial reconstituted with 2mL of bacteriostatic water yields 2.5mg/mL (2,500mcg/mL) — 25mcg per unit on a standard 1mL (100-unit) insulin syringe.

Only three small human pilot studies exist for BPC-157, none randomized or placebo-controlled, and all report zero adverse events — a genuinely small evidence base.

A 2025 review states "only three pilot studies have examined BPC-157 in humans" and concludes the compound "should be considered investigational" pending larger trials. McGuire et al., Curr Rev Musculoskelet Med, 2025 None of the human pilots used the subcutaneous route — the most common self-administered route in practice — meaning there is no published human safety data for that specific route.

An intravenous safety pilot (n=2) additionally tested heart, liver, kidney, thyroid, and blood-glucose biomarkers with no measurable negative effect. Lee & Burgess, Alt Ther Health Med, 2025

Cancer/angiogenesis: BPC-157's angiogenic mechanism is the basis for a theoretical concern about use during active malignancy. No study — in humans or animals — has actually evaluated BPC-157 in the context of active cancer. This is a mechanism-based theoretical question, not a documented adverse outcome either way.

There is no published human timeline for BPC-157 use. What follows is animal-model biology, not a human recovery prediction.

• Traumatic brain injury — animal studies: effects observed within a 24-hour post-injury window.
• Tendon repair — animal studies: progressive improvement assessed at days 1, 4, 7, 10, and 14.
• Muscle crush injury — animal studies: effects present at all measured intervals across 14 days.
• Complete muscle transection — animal studies: improvement sustained across a 72-day period.

Animals metabolize and heal faster than humans, with different tissue architecture — a day-14 result in an animal tendon study doesn't mean a comparable human outcome at two weeks. Any specific human week-by-week timeline seen elsewhere in this space is anecdotal, not derived from a study.

The two are frequently stacked together, but the evidence bases behind them differ:

What each is: BPC-157 is a stable, gastric-derived 15-amino-acid peptide studied largely intact. TB-500 is a 7-amino-acid fragment of a much larger parent protein (Thymosin Beta-4) — and almost none of the published research was conducted on that fragment itself, only on the full parent protein.

Human evidence: BPC-157 has three small human pilot studies on the actual compound. TB-500's only human clinical data is on full-length Tβ4 delivered as an eye drop — zero human data exists for the TB-500 fragment itself.

Mechanism: BPC-157 centers on nitric oxide signaling and VEGFR2-driven angiogenesis. TB-500/Tβ4 centers on G-actin sequestration, directly regulating the actin cytoskeleton to drive cell migration.

BPC-157 has the stronger — if still small — real-world human safety record on the actual product sold. TB-500's supporting literature is substantial but almost entirely about a different, larger molecule than what's in the vial.